European Society of Medical Oncology

ESMO 2021

This program was supported by Bayer Inc.

prostate cancer conference highlights

AUDIO & VIDEO CAPSULES

Moderated by Dr. Jason Izard

This conference is available through our podcast

How to subscribe

Abstract Summaries

Dr Aly-Khan Lalani

Abstract LBA5 – A phase 3 trial with a 2×2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1

ESMO 2021

Dr Aly-Khan Lalani

00:00 / 15:10

Download Dr. Aly-Khan Lalani summary

[rating_form id="30" custom_id="emso-2021-lalani" score="false" total="false" stats="false" before_content="Rate this summary:"]

Watch video capsule

Abstract Summaries

Dr. Geoffrey Gotto

Abstract LBA4 – Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

ESMO 2021

Dr. Geoffrey Gotto

00:00 / 9:09

Download Dr. Geoffrey Gotto summary

[rating_form id="31" custom_id="emso-2021-gotto" score="false" total="false" stats="false" before_content="Rate this summary:"]

Watch video capsule

Abstract Summaries

Dr. Maria Jiang

Abstract LBA25 – Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

ESMO 2021

Dr. Maria Jiang

00:00 / 12:55

Download Dr. Maria Jiang summary

[rating_form id="32" custom_id="emso-2021-jiang" score="false" total="false" stats="false" before_content="Rate this summary:"]

Watch video capsule

Abstract Summaries

Dr. Jenny Ko

Abstract LBA26 – Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16)

ESMO 2021

Dr. Jenny Ko

00:00 / 7:57

Download Dr. Maria Jiang summary

[rating_form id="33" custom_id="emso-2021-jenny-ko" score="false" total="false" stats="false" before_content="Rate this summary:"]

Watch video capsule

Abstract Summaries

Dr. Andre-Guy Martin

Abstract 576MO – Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

ESMO 2021

Dr. Andre-Guy Martin

00:00 / 7:29

Download Dr. Andre-Guy Martin summary

[rating_form id="34" custom_id="emso-2021-martin" score="false" total="false" stats="false" before_content="Rate this summary:"]

Watch video capsule

The opinions expressed in these capsules are those of the physicians.